An estimated 55 million people worldwide live with dementia, a number that’s expected to rise as the global population ages. To find treatments that can slow or stop the disease, scientists need to better understand the factors that can cause dementia.
Researchers at Tufts University have completed the first study examining levels of vitamin D in brain tissue, specifically in adults who suffered from varying rates of cognitive decline. They found that members of this group with higher levels of vitamin D in their brains had better cognitive function. The study was published December 7 in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
“This research reinforces the importance of studying how food and nutrients create resilience to protect the aging brain against diseases such as Alzheimer’s disease and other related dementias,” said senior and corresponding author Sarah Booth, director of the Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts and lead scientist of the HNRCA’s Vitamin K Team.
Vitamin D supports many functions in the body, including immune responses and maintaining healthy bones. Dietary sources include fatty fish and fortified beverages (such as milk or orange juice); brief exposure to sunlight also provides a dose of vitamin D.
“Many studies have implicated dietary or nutritional factors in cognitive performance or function in older adults, including many studies of vitamin D, but all of them are based on either dietary intakes or blood measures of vitamin D,” said lead author Kyla Shea, a scientist on the Vitamin K Team and an associate professor at the Friedman School of Nutrition Science and Policy at Tufts. “We wanted to know if vitamin D is even present in the brain, and if it is, how those concentrations are linked to cognitive decline.”
Booth, Shea, and their team examined samples of brain tissue from 209 participants in the Rush Memory and Aging Project, a long-term study of Alzheimer’s disease that began in 1997. Researchers at Rush University assessed the cognitive function of the participants, older people with no signs of cognitive impairment, as they aged, and analyzed irregularities in their brain tissue after death.
In the Tufts study, researchers looked for vitamin D in four regions of the brain—two associated with changes linked to Alzheimer’s disease, one associated with forms of dementia linked to blood flow, and one region without any known associations with cognitive decline related to Alzheimer’s disease or vascular disease. They found that vitamin D was indeed present in brain tissue, and high vitamin D levels in all four regions of the brain correlated with better cognitive function.
However, the levels of vitamin D in the brain didn’t associate with any of the physiological markers associated with Alzheimer’s disease in the brain studied, including amyloid plaque buildup, Lewy body disease, or evidence of chronic or microscopic strokes. This means it’s still unclear exactly how vitamin D might affect brain function.
“Dementia is multifactorial, and lots of the pathological mechanisms underlying it have not been well characterized,” Shea says. “Vitamin D could be related to outcomes that we didn’t look at yet, but plan to study in the future.”
Vitamin D is also known to vary between racial and ethnic populations, and most of the participants in the original Rush cohort were white. The researchers are planning followup studies using a more diverse group of subjects to look at other brain changes associated with cognitive decline. They hope their work leads to a better understanding of the role vitamin D may play in staving off dementia.
However, experts caution people not to use large doses of vitamin D supplements as a preventive measure. The recommended dose of vitamin D is 600 IU for people 1-70 years old, and 800 IU for those older—excessive amounts can cause harm, and have been linked to the risk of falling.
“We now know that vitamin D is present in reasonable amounts in human brains, and it seems to be correlated with less decline in cognitive function,” Shea says. “But we need to do more research to identify the neuropathology that vitamin D is linked to in the brain before we start designing future interventions.”
Research reported in this article was supported by the National Institutes of Health’s National Institute on Aging under award numbers R01AG051641 and R01AG17917, as well as the U.S. Department of Agriculture’s Agricultural Research Service. Complete information on authors, funders, and conflicts of interest is available in the published paper. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the U.S. Department of Agriculture.
Journal
Alzheimer s & Dementia
Subject of Research
Human tissue samples
Article Title
Brain Vitamin D Forms, Cognitive Decline and Neuropathology in Community-dwelling Older Adults
Article Publication Date
7-Dec-2022
COI Statement
MKS, BDH, XF, SLB are supported by NIH grants (to Tufts University). KB is a member of the American Society of Nutrition Statistical Review Board, served on NIH Study Section Review Committee, and receives support from the Bill and Melinda Gates Foundation, the Edward N. and Della L. Thome Memorial Foundation and NIH (all to Tufts University). SEL is a Biostatistics Editor of Neurology, served on NIH Study Section Review Committees and is supported by NIH grants (to Rush University). BDJis a consultant for the Alzheimers Association. TMH is a member of the U.S. Against Alzheimer’s non-profit risk reduction work. PA receives support from the Michael J Fox Foundation, the Physicians Committee for Responsible Medicine and is a member of the US against Alzheimer's non-profit risk reduction working group. JAS receives support from Alnylam, Eli Lily, and for expert legal testimony, serves on External Advisory Committees for Kansas University, Boston University, University of California Irvine, University of Washington, New York University and Observational Monitoring Boards for Framingham Heart study and NINDS Discovery at Boston University and is supported by NIH grants (to Rush University). All other co-authors have nothing to disclose.